Tonghe Pharmaceutical announced that the company recently received a notification of the GMP compliance test results from the Jiangxi Drug Administration, and learned that the company's active ingredient agomelatine complies with the GMP drug. The scope of inspection is APIs, and the inspection date is November 4-6, 2024. Agomelatine is indicated for treating depression in adults. The company's active ingredient, agomelatine, has passed the GMP compliance test, which helps the company expand sales of products in the domestic market.

Tonghe Pharmaceutical announced that the company recently received a notification of the GMP compliance test results from the Jiangxi Drug Administration, and learned that the company's active ingredient agomelatine complies with the GMP drug. The scope of inspection is APIs, and the inspection date is November 4-6, 2024. Agomelatine is indicated for treating depression in adults. The company's active ingredient, agomelatine, has passed the GMP compliance test, which helps the company expand sales of products in the domestic market.